This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD. Five hundred and fifty-two (552) evaluable subjects will be enrolled in this study, and will undergo SPECT MPI and Flurpiridaz (18F) Injection PET MPI, prior to ICA. Patients can be considered for enrolment if: - They are being scheduled via written documentation at the time of enrolment to undergo ICA, and - They have undergone a clinically indicated SPECT study which meets all study-specified imaging and stress testing criteria, or are willing to undergo SPECT MPI for the purposes of the clinical study.

You may be eligible for this study if you meet the following criteria:

• Conditions: Coronary Artery Disease
• Age: 18 years - 99 years
• Gender: All